Musculoskeletal Diseases
Conditions
Interventions
Diclofenac Sodium
GC 500
Sponsors
Department of Herbal Medicine Kwame Nkrumah University of Science and Technology
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Male or female between the ages of 45 to 75 years Patients clinically diagnosed with a chronic pain from an osteoarthritis. Patients with a history of primary idiopathic osteoarthritis of any joint characterised by pain of mild to moderate intensity and requiring the intake of analgesics, recurrent pain in any of the major joints for more than 6 months.
Exclusion criteria
Exclusion criteria: Individuals whose pain were of metastatic origin Patients receiving an opioid or steroid based treatment. Participants with clinically significant diseases such as an endocrine, autoimmune disorder and a pre-existing cardiovascular risk. Individuals with hepatic and renal impairment as well as the acutely ill
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome of this study was a reduction in the baseline disease grading, Graded Chronic Pain Score, to Grade 0 by the end of the 8th week for all participants. | — |
Secondary
| Measure | Time frame |
|---|---|
| The potential of the product to reduce the physical and socioeconomic impact of the disease represented by a reduction in either the Characteristic Pain Intensity and/or a decline in the Disability Points. | — |
Countries
Ghana
Contacts
Public ContactAma Kyeraa Thomford
Department of Biomedical Science UCC
Outcome results
None listed